The company has 1 employees. Beneficial owners: Kārlis Ūdris.
| year | 2024Latest | 2023 | 2022 |
|---|---|---|---|
Revenue | 0 € | 0 € | 0 € |
Profit | 20,8k € +125.5% | -81,4k € -108.0% | -39,1k € |
Assets | 308k € +45.8% | 211,2k € +1204.5% | 16,2k € |
Liabilities | 277,6k € -0.5% | 279k € +431.2% | 52,5k € |
Equity | 30,4k € +144.9% | -67,8k € -86.6% | -36,3k € |
Employees | 1 +0.0% | 1 +0.0% | 1 |
Overall rating | A88/100 |
Financial health | 100/100 |
Credit history | 80/100 |
Legal history | 100/100 |
Business activity | 60/100 |
| Overall risk | Low |
No risk flags | |
No tax debts | |
Positive profit | |
Regular report filing | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| Board member | Independently |
Project count
48
Total funding
€78 678 168
EU support
€45 000 000
| Project | Period | Role | Funding received | Status |
|---|---|---|---|---|
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
Inovatīvu produktu un tehnoloģiju izstrāde Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centra ietvaros 1.2.1.2.i.2/1/24/A/CFLA/005 Program: AF | 2024. gada 2. jūlijs until 2027. gada 31. decembris | partner | - | Līgums |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
1.2.1.2.i.2/1/24/A/CFLA/005 | - | partner | - | - |
SIA "Elogium Probiotics" is located at Ropažu nov., Garkalnes pag., Berģi, Lapu iela 3B, LV-1024.
In 2024, SIA "Elogium Probiotics" had an average of 1 employees. View tax history →
The beneficial owners of SIA "Elogium Probiotics" are Kārlis Ūdris. View ownership details →
Yes, SIA "Elogium Probiotics" is registered as an active VAT payer with VAT number LV40203344445.
In 2024, the average gross salary at SIA "Elogium Probiotics" was approximately 1892,05 € per month (net ~ 1391,62 €). This is an approximate calculation. View salary details →
SIA "Elogium Probiotics" was founded on September 9, 2021. The company has been operating for 5 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 5 years | 22 - 26 | 12% | |
Profit | 20 797,00 € | 8 - 12 | 65% | |
Equity | 30 436,00 € | 15 - 19 | 20% | |
Assets | 308 028,00 € | 8 - 12 | 64% | |
Liquidity | 3.06 | - | 90% | |
Registered capital | 2916,50 € | - | 10% |
Annual financial report for 2024.
Annual financial report for 2023.
Annual financial report for 2022.
Registered in the Latvian company register.
| Name, surname | Birth date | Shares | Ownership rights | |
|---|---|---|---|---|
| Mulec Ines Mandic | - | 42 000 | 14.40% | |
| Katarina Šimunovic | - | 42 000 | 14.40% | |
| Polonca Štefanič | - | 42 000 | 14.40% | |
| Kārlis Ūdris | 126 000 | 43.20% | ||
| "Commercialization Reactor Residents" | - | 21 000 | 7.20% | |
| KS "Commercialization Reactor Pre-seed Fund" AIF | - | 18 650 | 6.39% | |
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Kārlis Ūdris | LV |